We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Read MoreHide Full Article
For the quarter ended June 2023, Boston Scientific (BSX - Free Report) reported revenue of $3.6 billion, up 10.9% over the same period last year. EPS came in at $0.53, compared to $0.44 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $3.5 billion, representing a surprise of +2.88%. The company delivered an EPS surprise of +8.16%, with the consensus EPS estimate being $0.49.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Geographic Revenue- U.S. $2.11 billion compared to the $2.07 billion average estimate based on four analysts. The reported number represents a change of +9.2% year over year.
Net Sales- Cardiovascular- Cardiac Rhythm Management- United States: $356 million compared to the $352.96 million average estimate based on three analysts. The reported number represents a change of +4.1% year over year.
Net Sales- Cardiovascular- Peripheral Interventions- United States: $285 million versus $285.45 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.9% change.
Net Sales- Cardiovascular- Peripheral Interventions- International: $250 million versus the three-analyst average estimate of $238.29 million. The reported number represents a year-over-year change of +13.1%.
Net Sales- Cardiovascular- Worldwide: $2.24 billion compared to the $2.14 billion average estimate based on seven analysts. The reported number represents a change of +12.2% year over year.
Net Sales- MedSurg- Worldwide: $1.36 billion compared to the $1.34 billion average estimate based on seven analysts. The reported number represents a change of +9% year over year.
Net Sales- MedSurg- Neuromodulation- Worldwide: $244 million versus the six-analyst average estimate of $248.78 million. The reported number represents a year-over-year change of +2.1%.
Net Sales- Cardiovascular- Peripheral Interventions- Worldwide: $535 million versus the six-analyst average estimate of $517.41 million. The reported number represents a year-over-year change of +11.9%.
Net Sales- Cardiovascular- Cardiology- Worldwide: $1.70 billion versus $1.63 billion estimated by six analysts on average.
Net Sales- MedSurg- Urology- Worldwide: $485 million versus the six-analyst average estimate of $479.18 million. The reported number represents a year-over-year change of +7.8%.
Net Sales- MedSurg- Endoscopy- Worldwide: $631 million compared to the $614.45 million average estimate based on six analysts. The reported number represents a change of +12.7% year over year.
Net Sales- Cardiovascular- Cardiac Rhythm Management- Worldwide: $566 million compared to the $550.92 million average estimate based on five analysts. The reported number represents a change of +4.6% year over year.
Shares of Boston Scientific have returned -2% over the past month versus the Zacks S&P 500 composite's +5.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific (BSX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended June 2023, Boston Scientific (BSX - Free Report) reported revenue of $3.6 billion, up 10.9% over the same period last year. EPS came in at $0.53, compared to $0.44 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $3.5 billion, representing a surprise of +2.88%. The company delivered an EPS surprise of +8.16%, with the consensus EPS estimate being $0.49.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- U.S. $2.11 billion compared to the $2.07 billion average estimate based on four analysts. The reported number represents a change of +9.2% year over year.
- Net Sales- Cardiovascular- Cardiac Rhythm Management- United States: $356 million compared to the $352.96 million average estimate based on three analysts. The reported number represents a change of +4.1% year over year.
- Net Sales- Cardiovascular- Peripheral Interventions- United States: $285 million versus $285.45 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +10.9% change.
- Net Sales- Cardiovascular- Peripheral Interventions- International: $250 million versus the three-analyst average estimate of $238.29 million. The reported number represents a year-over-year change of +13.1%.
- Net Sales- Cardiovascular- Worldwide: $2.24 billion compared to the $2.14 billion average estimate based on seven analysts. The reported number represents a change of +12.2% year over year.
- Net Sales- MedSurg- Worldwide: $1.36 billion compared to the $1.34 billion average estimate based on seven analysts. The reported number represents a change of +9% year over year.
- Net Sales- MedSurg- Neuromodulation- Worldwide: $244 million versus the six-analyst average estimate of $248.78 million. The reported number represents a year-over-year change of +2.1%.
- Net Sales- Cardiovascular- Peripheral Interventions- Worldwide: $535 million versus the six-analyst average estimate of $517.41 million. The reported number represents a year-over-year change of +11.9%.
- Net Sales- Cardiovascular- Cardiology- Worldwide: $1.70 billion versus $1.63 billion estimated by six analysts on average.
- Net Sales- MedSurg- Urology- Worldwide: $485 million versus the six-analyst average estimate of $479.18 million. The reported number represents a year-over-year change of +7.8%.
- Net Sales- MedSurg- Endoscopy- Worldwide: $631 million compared to the $614.45 million average estimate based on six analysts. The reported number represents a change of +12.7% year over year.
- Net Sales- Cardiovascular- Cardiac Rhythm Management- Worldwide: $566 million compared to the $550.92 million average estimate based on five analysts. The reported number represents a change of +4.6% year over year.
View all Key Company Metrics for Boston Scientific here>>>Shares of Boston Scientific have returned -2% over the past month versus the Zacks S&P 500 composite's +5.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.